Bristol Myers Squibb (CELG-RI) Dividends payables (2009 - 2015)
Bristol Myers Squibb (CELG-RI) reported Dividends payables of $655.0 million for Q4 2015, up 1.55% year-over-year from $645.0 million in Q4 2014, and up 2.99% quarter-over-quarter from $636.0 million in Q3 2015.
Bristol Myers Squibb (CELG-RI) Dividends payables (2009 - 2015) Analysis & Trends
Bristol Myers Squibb (CELG-RI) has 7 years of Dividends payables data on file, last reported at $655.0 million in Q4 2015.
- Dividends payables for Q4 2015 came in at $655.0 million, up 1.55% year-over-year; the trailing twelve-month figure through Dec 2015 was $655.0 million (up 1.55% YoY), and the FY2015 annual result was $655.0 million, up 1.55% from the prior year.
- Dividends payables grew to $655.0 million in Q4 2015 per CELG-RI's latest filing, from $636.0 million in the prior quarter.
- Over five years, Dividends payables peaked at $655.0 million in Q4 2015 and troughed at $578.0 million in Q1 2011.
- A 5-year average of $612.2 million and a median of $608.5 million in 2012 frame the typical range for Dividends payables.
- On a YoY basis, Dividends payables climbed as much as 4.62% in 2013 and fell as far as 1.34% in 2013.
- A 5-year view of Dividends payables shows it stood at $597.0 million in 2011, then gained by 1.51% to $606.0 million in 2012, then increased by 4.62% to $634.0 million in 2013, then climbed by 1.74% to $645.0 million in 2014, then increased by 1.55% to $655.0 million in 2015.
- Business Quant data shows CELG-RI's Dividends payables at $655.0 million in Q4 2015, $636.0 million in Q3 2015, and $634.0 million in Q2 2015.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Dividends payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | - |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | - |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | - |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | 2.14 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | - |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | - |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | - |
| 10 | Bristol Myers Squibb | - | - | 8.07 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2015 | 655.00 Mn |
| Sep 30, 2015 | 636.00 Mn |
| Jun 30, 2015 | 634.00 Mn |
| Mar 31, 2015 | 633.00 Mn |
| Dec 31, 2014 | 645.00 Mn |
| Sep 30, 2014 | 623.00 Mn |
| Jun 30, 2014 | 621.00 Mn |
| Mar 31, 2014 | 619.00 Mn |
| Dec 31, 2013 | 634.00 Mn |
| Sep 30, 2013 | 611.00 Mn |
| Jun 30, 2013 | 606.00 Mn |
| Mar 31, 2013 | 601.00 Mn |
| Dec 31, 2012 | 606.00 Mn |
| Sep 30, 2012 | 596.00 Mn |
| Jun 30, 2012 | 598.00 Mn |
| Mar 31, 2012 | 593.00 Mn |
| Dec 31, 2011 | 597.00 Mn |
| Sep 30, 2011 | 578.00 Mn |
| Jun 30, 2011 | 579.00 Mn |
| Mar 31, 2011 | 578.00 Mn |